FDA Panel Gets Varied Opinions on DTC Genomics | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Advisers for the US Food and Drug Administration this week heard arguments and recommendations about how it should approach direct-to-consumer genetic testing, with some parties making the case for little or no regulation, others seeking tighter controls, and some proposing a stratified regulatory scheme.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.